[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472762":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":59,"collaborators":13,"id":61,"slug":13,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":13,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":13,"studyType":72,"phases":73,"briefSummary":74,"conditions":75,"keywords":13,"overallStatus":45,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Standardized uptake value（SUV）","SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （68Ga-ACN376） in solid tumor lesions by measuring SUV on PET\u002FCT.","2 years",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","SCREENING",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"68Ga-ACN376","EXPERIMENTAL","Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET\u002FCT scan.",[26],"Drug: 18F-FDG",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":13},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[22],[34],{"name":35,"affiliation":5,"role":36},"Hua Zhu","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":13,"email":41},"CONTACT","010-88196495","zhuhuabch@pku.edu.cn",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Beijing cancer hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":35,"role":39,"phone":40,"phoneExt":13,"email":41},{"type":36,"investigatorFullName":35,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Associate Professor","100472762",false,"NCT05436093","CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged \\>18 years old; ECOG 0 or 1;\n* 2\\. Patients with solid tumors;\n* 3\\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);\n* 4\\. life expectancy \\>=12 weeks.\n\nExclusion Criteria:\n\n* 1\\. Significant hepatic or renal dysfunction;\n* 2\\. Is pregnant or ready to pregnant;\n* 3\\. Cannot keep their states for half an hour;\n* 4\\. Refusal to join the clinical study;\n* 5\\. Suffering from claustrophobia or other mental diseases;\n* 6\\. Any other situation that researchers think it is not suitable to participate in the experiment.","ALL","18 Years","75 Years",{"count":70,"type":71},15,"ESTIMATED","INTERVENTIONAL",[15],"The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET\u002FCT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.",[76],"Solid Tumor","2026-03-02",{"date":79,"type":80},"2026-03-04","ACTUAL",{"date":82,"type":80},"2022-06-23",{"date":84,"type":71},"2027-12",{"name":5,"class":6},1]